Advertise on podcast: Research To Practice | Oncology Videos

Featuring an interview with Dr Matthew Lunning, including the following topics: Bispecific antibody/antibody-drug conjugate combinations (0:00) A man in his late 90s with mantle cell lymphoma — Ann LaCasce, MD, MMSc (8:07) CME information and select publications

Featuring a presentation by Dr Matthew Matasar, including the following topics: Selection of First-Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) (0:00) Clinician Survey Results Regarding First-Line Treatment of DLBCL (11:41) Current and Future Roles of Monoclonal and Bispecific Antibodies in Therapy for Relapsed/Refractory (R/R) DLBCL (16:01) Clinician Survey Results Regarding the Use of Monoclonal and Bispecific Antibodies for R/R DLBCL (28:47) Evidence-Based Incorporation of Antibody-Drug Conjugates (ADCs) into the Management of R/R DLBCL (34:34) Clinician Survey Results Regarding the Use of ADCs for R/R DLBCL (46:31) Discussion of Questions from the Community (50:20) CME information and select publications

Featuring an interview with Dr Matthew Lunning, including the following topics: A woman in her late 70s with non-GCB diffuse large B-cell lymphoma receives pola-R-CHP — Ann LaCasce, MD, MMSc (0:00) CNS prophylaxis in non-Hodgkin lymphoma (7:58) CME information and select publications

Featuring an interview with Dr Erica Mayer, including the following topics: Risk Assessment and Genomic Assays for Hormone Receptor (HR)-Positive, HER2-Negative Localized Breast Cancer (0:00) Investigator Survey Results on Risk Assessment and Genomic Assays (20:07) Adjuvant CDK4/6 Inhibitors for High-Risk, HR-Positive, HER2-Negative Localized Breast Cancer (24:30) Investigator Survey Results on Adjuvant CDK4/6 Inhibitors (30:42) Tolerability and Other Practical Considerations with Adjuvant CDK4/6 Inhibitor Therapy (32:07) Investigator Survey Results on Tolerability and Other Practical Considerations with Adjuvant CDK4/6 Inhibitor Therapy (37:44) Adjuvant Oral Selective Estrogen Receptor Degraders (SERDs) for HR-Positive, HER2-Negative Localized Breast Cancer (39:05) Investigator Survey Results on Adjuvant Oral SERDs (43:02) Discussion of Questions from the Community (45:00) CME information and select publications

Featuring perspectives from Dr Lindsey Roeker, including the following topics: Case: A man in his mid 60s with TP53-aberrant chronic lymphocytic leukemia (CLL) with extensive marrow infiltration receives first-line venetoclax/obinutuzumab and experiences an excellent response (0:00) Case: A man in his late 70s with small lymphocytic lymphoma (SLL) and cardiovascular comorbidities requiring verapamil and anticoagulation receives acalabrutinib/venetoclax; Case: A man in his early 80s with SLL receives zanubrutinib/sonrotoclax as part of the CELESTIAL-TNCLL trial (14:46) Case: A man in his late 70s with progressive CLL worsening after a skiing injury receives acalabrutinib/venetoclax as part of the MAJIC trial (22:37) CME information and select publications

Featuring perspectives from Dr Lindsey Roeker, including the following topics: Consensus Approach to optimizing front-line treatment (0:00) Emerging role of sonrotoclax (8:39) Bruton tyrosine kinase inhibitor monotherapy for older patients; discontinuation (14:48) Evolving role of minimal residual disease assessment (19:16) CME information and select publications

Featuring perspectives from Dr Nicoletta Colombo, Dr Gottfried E Konecny, Dr Alexander B Olawaiye and Dr Shannon N Westin, moderated by Dr Westin, including the following topics: Case: A woman in her early 70s with endometrioid carcinoma of the ovary and a large solitary brain metastasis after primary debulking surgery and adjuvant carboplatin/paclitaxel — Professor Jonathan A Ledermann (0:00) CME information and select publications

Featuring perspectives from Dr Nicoletta Colombo, Dr Gottfried E Konecny, Dr Alexander B Olawaiye and Dr Shannon N Westin, moderated by Dr Westin, including the following topics: Case: A woman in her late 60s with a germline BRCA2 mutation and heavily pretreated ovarian cancer receives weekly nab paclitaxel and relacorilant — Angeles Alvarez Secord, MD, MHSc (0:00) CME information and select publications

Featuring an interview with Prof Karim Fizazi, including the following topics: Perspectives on the PROTEUS Phase III trial evaluating the addition of apalutamide to standard therapy for high-risk localized prostate cancer (0:00) Mechanism of action of opevesostat and potential role in castration-resistant prostate cancer with androgen receptor mutations (15:37) Perspectives on alpha- and beta-emitting radiopharmaceuticals in the treatment of prostate cancer (22:47) Novel antibody-drug conjugates and proteolysis-targeting chimeras (30:43) Treatment approaches for metastatic hormone-sensitive prostate cancer — de novo symptomatic presentation versus PSMA-only metastatic recurrence after local therapy (34:51) Role of intermittent therapy in the treatment of prostate cancer (38:48) Treatment intensification approaches in prostate cancer (41:38) Case: A man in his late 60s with de novo PSMA PET-positive metastatic castration-sensitive prostate cancer (45:25) CME information and select publications

Featuring a slide presentation and related discussion from Prof Karim Fizazi, including the following topics: PROTEUS Phase III trial evaluating the addition of apalutamide to standard therapy in high-risk localized prostate cancer (0:00) Time to testosterone recovery during treatment suspension in the Phase III EMBARK trial of enzalutamide and leuprolide in nonmetastatic prostate cancer (5:05) Radiographic progression-free survival subgroup analysis in the PSMAddition Phase III trial of 177Lu-PSMA-617 in metastatic hormone-sensitive prostate cancer (6:58) TALAPRO-3: Efficacy of talazoparib and enzalutamide in metastatic hormone-sensitive prostate cancer harboring homologous recombination repair gene alterations (8:16) Phase I/II PETRANHA study of novel PARP inhibitor saruparib in metastatic hormone-sensitive prostate cancer (10:52) Phase II A-DREAM trial of androgen deprivation therapy interruption in patients with metastatic hormone-sensitive prostate cancer responding to androgen receptor pathway inhibitor (13:23) Overall survival by duration of enzalutamide treatment received in the Phase III ARCHES trial (15:21) Efficacy of capivasertib and abiraterone in the Phase III CAPItello-281 trial for patients with PTEN-deficient metastatic hormone-sensitive prostate cancer (16:24) Phase I AcTION study of 225Ac-PSMA-617 in patients with metastatic castration-resistant prostate cancer (mCRPC) with or without prior 177Lu-PSMA radioligand therapy (18:16) Phase III PSMAfore trial of 177Lu-PSMA-617 in progressive mCRPC; ongoing Phase III trials of radioligands in mCRPC (19:54) Ongoing Phase III OMAHA-004 trial of CYP11 inhibitor opevesostat versus next-generation hormonal agent switch in patients with mCRPC and 1 prior next-generation hormonal agent (23:14) CME information and select publications

Featuring perspectives from Prof Susana Banerjee, including the following topics: Case: A woman in her mid 50s with multiregimen-recurrent low-grade serous ovarian cancer and a KRAS G12V mutation who receives avutometinib/defactinib with response, asymptomatic creatine phosphokinase elevation and mild facial rash — Dr Stover (0:00) Case: A woman in her early 30s with recurrent metastatic low-grade serous ovarian cancer, originally offered hospice due to poor condition, who receives avutometinib/defactinib with an excellent response — Dr Hussein (7:58) Case: A woman in her late 30s with multiregimen-recurrent folate receptor alpha-positive low-grade serous ovarian cancer (HER2 IHC 2+) who receives mirvetuximab soravtansine — Dr Cobb (18:21) CME information and select publications

Featuring perspectives from Prof Susana Banerjee, including the following topics: Overview of the biology and treatment of low-grade serous ovarian cancer (0:00) Mechanism of action of avutometinib/defactinib (10:16) RAMP 201 Trial: Avutometinib/defactinib in recurrent low-grade serous ovarian cancer (14:32) Ongoing clinical trials in low-grade serous ovarian cancer (27:57) CME information and select publications

Featuring perspectives from Dr Spencer Bachow, Dr Bhavana (Tina) Bhatnagar, Dr Jennifer Crombie, Dr Manali Kamdar and Ms Alexandra Lynch, co-moderated by Dr Bachow and Dr Bhatnagar, including the following topics: Introduction and Overview of Bispecific Antibodies in the Clinic (0:00) Current and Future Role of Bispecific Antibodies in Non-Hodgkin Lymphoma — Dr Kamdar (15:58) Case: A man in his early 60s with diffuse large B-cell lymphoma (DLBCL) receives glofitamab (42:40) Case: A woman in her early 80s with follicular lymphoma (FL) receives mosunetuzumab (51:50) Mitigation and Management of Cytokine Release Syndrome (CRS) and Other Toxicities Associated with Bispecific Antibodies — Dr Crombie (1:00:39) Case: A woman in her early 80s with DLBCL receives glofitamab (1:18:50) Case: A woman in her early 70s with FL receives epcoritamab (1:26:38) Outpatient CRS Management in B-Cell Lymphomas — Ms Lynch (1:29:28) Case: A woman in her late 40s with FL receives epcoritamab (1:38:33) Case: A man in his early 70s with mantle cell lymphoma receives mosunetuzumab (1:46:26) CME information and select publications

Featuring a slide presentation from Dr Julia Rotow, including the following topics: Rationale and potential clinical role of PD-1/PD-L1 x vascular endothelial growth factor (VEGF) bispecific antibodies in the treatment of non-small cell lung cancer (NSCLC) (0:00) Key findings from the Phase III HARMONi-6 study; ongoing Phase III HARMONi-3 study (5:12) Key findings from the Phase III HARMONi-2 study; ongoing Phase III HARMONi-7 study (9:59) Clinician insights about the potential role of ivonescimab in the front-line setting (12:02) Impetus for investigating ivonescimab in the relapsed/refractory (R/R) EGFR-mutant setting (14:01) Key findings from the Phase III HARMONi-A and HARMONi studies (16:07) Clinician insights about the potential role of ivonescimab in the treatment of R/R EGFR-mutant NSCLC; other novel PD-1/PD-L1 x VEGF bispecific antibodies under investigation (20:30) CME information and select publications

Featuring perspectives from Dr Catherine C Coombs, including the following topics: Phase III BRUIN CLL-322 trial of fixed-duration pirtobrutinib in combination with venetoclax and rituximab for previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) (0:00) Role of allogeneic hematopoietic cell transplantation and chimeric antigen receptor T-cell therapy for relapsed/refractory (R/R) CLL (10:42) Fixed-duration venetoclax in combination with epcoritamab for R/R CLL/SLL; management of Richter's transformation (15:50) Novel Bruton tyrosine kinase degraders bexobrutideg (NX-5948) and tacabrutideg (BGB-16673) (22:51) CME information and select publications